Placing the patient at the heart of discovery science
The development of digital technologies for data acquisition and storage, coupled with the emergence of new molecular platforms and enhanced capacities in data science, have facilitated the decoding of molecular and cellular mechanisms underlying cancer progression, metastasis, and immune evasion using patient samples. Sample characterisation and analysis are now fully integrated in the discovery process, serving both as a validation tool (from bench to bedside) and as hypothesis-generating tool (inductive research). (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Mihaela Aldea, Elsa Bernard, Charles Swanton, Fabrice Andre Tags: Editorial Source Type: research
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer
Neoadjuvant immune checkpoint blockade (IO) is emerging as a therapeutic option for patients with deficient mismatch repair (dMMR) colorectal cancer (CRC) given high pathological response rates. The aim of the study was to characterise imaging and endoscopic response to IO. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Daniel A. Fox, Deepak Bhamidipati, Tsuyoshi Konishi, Harmeet Kaur, Nancy You, Kanwal P.S. Raghav, Phillip S. Ge, Craig Messick, Benny Johnson, Van K. Morris, Jane V. Thomas, Preksha Shah, Brian K. Bednarski, Scott Kopetz, George J. Chang, Kaysia Ludford, Tags: Original Research Source Type: research
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy
The ‘Table 1 Fallacy’ refers to the unsound use of significance testing to compare the distributions of baseline variables between randomised groups to draw erroneous conclusions about balance or imbalance. We performed a cross-sectional study of the Table 1 Fallacy in phase III oncology trials. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Alexander D. Sherry, Pavlos Msaouel, Zachary McCaw, Joseph A. Jaoude, Eric J. Hsu, Ramez Kouzy, Roshal Patel, Yumeng Yang, Timothy A. Lin, Cullen Taniguchi, Claus R ödel, Emmanouil Fokas, Chad Tang, C. David Fuller, Bruce Minsky, Tomer Meirson, Ryan Sun, Tags: Original Research Source Type: research
At the right dose: personalised (N-of-1) dosing for precision oncology
The objective of oncology therapeutics, especially in the age of precision medicine, is to give the right drug(s) to the right patient at the right time. Yet, a major challenge is finding the right dose for each patient. Determining safe and efficacious doses of oncology treatments, especially for novel combination therapies, can be challenging. Moreover, traditionally, dosing cancer drugs is based on giving each patient the same dose (a flat dose) or a dose based on surface area/weight. But patients ’ ability to tolerate drugs is influenced by additional factors including, but not limited to age, gender, race, comorbidi...
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Mina Nikanjam, Shumei Kato, Jason K. Sicklick, Razelle Kurzrock Tags: Current Perspective Source Type: research
At the Right Dose: Personalized (N-of-1) dosing for precision oncology
The objective of oncology therapeutics, especially in the age of precision medicine, is to give the right drug(s) to the right patient at the right time. Yet, a major challenge is finding the right dose for each patient. Determining safe and efficacious doses of oncology treatments, especially for novel combination therapies, can be challenging. Moreover, traditionally, dosing cancer drugs is based on giving each patient the same dose (a flat dose) or a dose based on surface area/weight. But patients ’ ability to tolerate drugs is influenced by additional factors including, but not limited to age, gender, race, co-morbid...
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Mina Nikanjam, Shumei Kato, Jason K. Sicklick, Razelle Kurzrock Tags: Current Perspective Source Type: research
Durable response to combination immunotherapy using Nivolumab and Ipilimumab in metastatic succinate dehydrogenase (SDH)- deficient gastrointestinal stroma tumour
The introduction of targeted therapy using c-kit and multityrosine kinase inhibitors has led to dramatic improvement in the outcome of patients with advanced gastrointestinal stroma tumours (GIST) over the last two decades [1]. Approximately 10% of GISTs are succinate dehydrogenase (SDH)- deficient either due to a germline or somatic mutation in the SDHA/B/C/D genes, or due to SDHC promotor methylation. The SDH-deficient GIST subgroup is associated with particular demographic features (younger age, female gender, stomach being primary tumour site) [2,3]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: O. Klein, J. Palmer, A. Behren, J. Cebon, D. Kee Tags: Letter Source Type: research
Prevalence and Implications of Significance Testing for Baseline Covariate Imbalance in Randomized Cancer Clinical Trials: The Table 1 Fallacy
The “Table 1 Fallacy” refers to the unsound use of significance testing to compare the distributions of baseline variables between randomized groups to draw erroneous conclusions about balance or imbalance. We performed a cross-sectional study of the Table 1 Fallacy in phase III oncology trials. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Alexander D. Sherry, Pavlos Msaouel, Zachary McCaw, Joseph Abi Jaoude, Eric J. Hsu, Ramez Kouzy, Roshal Patel, Yumeng Yang, Timothy A. Lin, Cullen Taniguchi, Claus R ödel, Emmanouil Fokas, Chad Tang, C. David Fuller, Bruce Minsky, Tomer Meirson, Ryan Sun Source Type: research
Long-Term Outcomes and Persistent Toxicities Following BRAF/MEK Inhibitor Therapy for Advanced Melanoma
Recent studies have shown that approximately 20% of patients have 4-5 year PFS on BRAF/MEK inhibitors. The long-term safety and efficacy in these patients with more durable responses have not been studied. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Rachel S. Goodman, Lorenza Di Guardo, Andrea Maurichi, Brendan Kirwin, Adnan Muhammad Khattak, Vito Vanella, Joanna Lee, Aleigha Lawless, Juliane Andrade Czapla, Andrea Spagnoletti, Margherita Ambrosini, Elisabeth Livingstone, Georgina V. Long, Ryan J. Su Tags: Original Research Source Type: research
Endoscopic and Imaging Outcomes of PD-1 Therapy in Localized dMMR Colorectal Cancer
Neoadjuvant immune checkpoint blockade (IO) is emerging as a therapeutic option for patients with deficient mismatch repair (dMMR) colorectal cancer (CRC) given high pathologic response rates. The aim of the study was to characterize imaging and endoscopic response to IO. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Daniel A. Fox, Deepak Bhamidipati, Tsuyoshi Konishi, Harmeet Kaur, Nancy You, Kanwal P.S. Raghav, Phillip S. Ge, Craig Messick, Benny Johnson, Van K. Morris, Jane V. Thomas, Preksha Shah, Brian K. Bednarski, Scott Kopetz, George J. Chang, Kaysia Ludford, Tags: Original Research Source Type: research
Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis
Neoadjuvant treatment discriminates responders, but pathologic complete response is uncommon in ER-positive/HER2-negative early breast cancer. We aimed to assess the prognostic value of Ki-67 index after neoadjuvant endocrine therapy (NET). (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Diogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, Lieveke Ameye, Marianne Paesmans, Michail Ignatiadis, Philippe Aftimos, Roberto Salgado, Evandro de Azambuja Tags: Original Research Source Type: research
Validation of the 2023 FIGO staging schema for advanced endometrial cancer
In 2023, the International Federation of Gynecology and Obstetrics (FIGO) revised the endometrial cancer staging schema [1]. This is the first revision in the past 15 years from prior revision occurred in 2009 [2]. One of the key changes is greater sub-division in advanced stages from 6 to 11 subgroups based on anatomical site of disease and histologic subtype (Table S1) [1]. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Koji Matsuo, Maximilian Klar, Bonnie B. Song, Lynda D. Roman, Jason D. Wright Tags: Letter to the Editor Source Type: research
Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study
It is unclear whether exposure to commonly prescribed medications influences survival and treatment response in patients with de novo high risk metastatic prostate cancer (mPCa) treated with androgen receptor pathway inhibitors (ARPIs). (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 20, 2023 Category: Cancer & Oncology Authors: Soumyajit Roy, Fred Saad, Christopher J.D. Wallis, Yilun Sun, Daniel E. Spratt, Rishav Akilla, Amar U. Kishan, Shawn Malone, Scott C. Morgan Tags: Original Research Source Type: research
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Dose optimisation is increasingly important in oncology, as exemplified by the US Food and Drug Administration ’s Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers as well as patients and physicians in lo w- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective and can be delivered...
Source: European Journal of Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Mark J. Ratain, Garth W. Strohbehn Tags: Current Perspective Source Type: research
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Dose optimisation is increasingly important in oncology, as exemplified by the US Food and Drug Administration ’s Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers as well as patients and physicians in lo w- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective and can be delivered...
Source: European Journal of Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Mark J. Ratain, Garth W. Strohbehn Tags: Current Perspective Source Type: research
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Dose optimization is increasingly important in oncology, as exemplified by the US Food and Drug Administration ’s Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers, as well as patients and physicians in lo w- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective, and can be delivered...
Source: European Journal of Cancer - September 19, 2023 Category: Cancer & Oncology Authors: Mark J. Ratain, Garth W. Strohbehn Source Type: research
